Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.97 USD | -5.29% | -10.45% | -48.56% |
05-02 | Acurx Pharmaceuticals, Inc. Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global Scientific Conference | CI |
04-04 | Top Premarket Gainers | MT |
Business Summary
Number of employees: 4
Managers
Managers | Title | Age | Since |
---|---|---|---|
Robert Shawah
FOU | Founder | 57 | 30/06/17 |
David Luci
FOU | Founder | 57 | 30/06/17 |
Chief Tech/Sci/R&D Officer | - | - | |
Lisa Wilson
IRC | Investor Relations Contact | - | - |
Mintz Levin
LAW | General Counsel | - | - |
Larry Mortin
PRN | Corporate Officer/Principal | - | - |
Xiang Yu
PRN | Corporate Officer/Principal | - | - |
Les Johnson
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Robert de Luccia
FOU | Founder | 78 | 30/06/17 |
Joseph Scodari
BRD | Director/Board Member | 71 | 23/06/21 |
Thomas Harrison
BRD | Director/Board Member | 76 | 23/06/21 |
David Luci
FOU | Founder | 57 | 30/06/17 |
Carl Sailer
BRD | Director/Board Member | 54 | 22/10/18 |
Jack Dean
BRD | Director/Board Member | 82 | 23/06/21 |
James J. Donohue
BRD | Director/Board Member | 54 | 23/06/21 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 15,823,102 | 13,418,479 ( 84.80 %) | 0 | 84.80 % |
Company contact information
Acurx Pharmaceuticals, Inc.
259 Liberty Avenue Staten Island
10305, New York
+917 533 1469
http://www.acurxpharma.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-48.56% | 32.91M | |
+21.74% | 46.81B | |
-0.97% | 41.37B | |
+47.07% | 41.29B | |
-3.52% | 28.87B | |
+11.12% | 26.06B | |
-19.37% | 19.13B | |
+31.18% | 12.39B | |
-0.04% | 12.08B | |
+0.39% | 11.96B |
- Stock Market
- Equities
- ACXP Stock
- Company Acurx Pharmaceuticals, Inc.